Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

21.08.2018 | original article | Ausgabe 19-20/2018 Open Access

Wiener klinische Wochenschrift 19-20/2018

Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer

A retrospective analysis

Zeitschrift:
Wiener klinische Wochenschrift > Ausgabe 19-20/2018
Autoren:
Eva Asamer, PD Dr. med. univ. Joanna Szkandera, Paul Gibiser, Dr. med. univ. Anna Lena Lembeck, Assoz. Prof. PD Dr. med. univ. Tatjana Stojakovic, Univ. Prof. Dr med. univ. Peter Kornprat, Univ. Prof. PD Dr. med. univ. Caroline Lackner, PD Dr. med. univ. Thomas Winder, Assoz. Dr. med. univ. Konstantin Schlick, Assoz. Univ. Prof. Dr. med. univ. Herbert Stöger, Assoz. Prof. Doz. PD Dr Armin Gerger, Assoz. Prof. PD Dr. Martin Pichler, FA Dr. med. univ. Dr. scient. med. Michael Stotz

Summary

Background and aim

The aim of this study was to investigate the prognostic relevance of plasma amylase and lipase concerning survival of patients suffering from metastatic pancreatic cancer (PC).

Method

This retrospective study included 351 patients with metastatic PC, who were treated in a single academic institution. Cancer-specific survival (CSS) was analyzed using the Kaplan-Meier method. To further evaluate the prognostic significance of lipase and amylase, univariate and multivariate values were calculated using Cox proportional models.

Results

In univariate analysis, an increased amylase level was associated with shorter CSS in PC patients (hazard ratio HR = 1.258; 95% confidence interval CI = 1.011–1.566; p = 0.039). In multivariate analysis, including gender, age, CA19-9 and administration of chemotherapy, increased amylase levels prevailed as an independent prognostic factor for CSS (HR = 1.373; 95%CI = 1.004–1.878; p = 0.047).

Conclusions

Plasma amylase was found to be an independent prognostic factor in patients with metastatic PC. The results indicate that amylase might represent a novel and useful marker for better patient stratification in PC management.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 19-20/2018

Wiener klinische Wochenschrift 19-20/2018 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

mitteilungen der gesellschaft der ärzte in wien

MUW researcher of the month

MUW researcher of the month